A Phase II Clinical Trial of DZD9008 in Combination With AZD4205 in Standard Treatment Failed NSCLC Patients With EGFR Mutations (WU-KONG21)

DZD9008 in combination with AZD4205 for the treatment of patients with advanced NSCLC with EGFR mutations who have progressed after standard treatment. The purpose of this study is to assess the safety and efficacy of this combination therapy.

Trial Details

NCT ID
NCT06295432
Phase
PHASE2
Sponsor
Dizal Pharmaceuticals
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • DZD9008+AZD4205
Locations (sample)
  • Guangzhou, Guangdong, China|23.11667,113.25
  • Wuhan, China|30.58333,114.26667
  • Xi'an, China|34.25833,108.92861
  • Zhengzhou, China|34.75778,113.64861

Key Eligibility Criteria

  • Patients must be able to understand the nature of the trial and provide a signed and dated informed consent form prior to screening.
  • Aged at least 18 years old when sign ICF.
  • Histological or cytological confirmed locally advanced or metastatic NSCLC.
  • Patients must exhibit Eastern Cooperative Oncology Group (ECOG) performance status 0 - 1 at ICF signature with no deterioration over the previous 2…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →